A Phase 1/2 study of induction therapy with Thalidomide, Melphalan and Prednisolone for newly diagnosed multiple myeloma patients ineligible for hematopoietic stem cell transplantation
Phase of Trial: Phase I/II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Thalidomide (Primary) ; Melphalan; Prednisolone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Fujimoto Pharmaceutical
- 31 Aug 2017 Status changed from active, no longer recruiting to completed.
- 16 Jun 2016 New trial record
- 30 Jul 2015 Status changed from recruiting to active, no longer recruiting.